the core of our corporate values
Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge" or "the Company", "2190.HK") announced on February 28 that it has received approval from Hong Kong Stock E...
On January 17, Zylox-Tonbridge (2190.HK, “the Company”) announced the completion of its strategic investment in Wire Sciences Medical Technology(Suzhou)Co., Ltd. (“Wire Sciences”). By leveraging its own s...
On December 13, Zylox-Tonbridge's postdoctoral workstation in cooperation with Zhejiang University (hereinafter referred to as "postdoctoral workstation”) was officially inaugurated.On the s...
Hangzhou, China, 29 November 2021- Zylox-Tonbridge (2190.HK, the “Company”) announced the last patient enrollment was completed for the clinical trial of “Tonbridge KylinTM” Flow Diverter (single ...
On November 16, 2021, Zylox-Tonbridge (2190.HK) successfully held the first Investor Day Event at its Hangzhou Headquarter. The event brought together more than 100 institutional investors and securit...
At the recent 2021 Oriental Conference of Interventional Neuroradiology (OCIN2021), Tonbridge Medical, the Neuro-intervention Business Division of Zylox-Tonbridge, successfully held the national launc...